Introduction {#Sec1}
============

Electrical stimulation has been used for many decades to activate paralyzed muscles. Muscle activation can be achieved by placement of electrodes on the surface of the skin or implanted within the muscle, near the motor point. Implanted neural stimulation devices (neuroprosthetics) have been used in spinal cord injury (SCI) for over 30 years. One implanted neuroprosthesis targeting hand grasp in individuals with tetraplegia, the Freehand system, was approved by the FDA in 1997 (PMA \#P950035) and commercialized by NeuroControl Corporation \[[@CR1], [@CR2]\]. The Freehand was demonstrated to be safe and effective, with users showing improvements in pinch force, ability to manipulate more every day objects, improved independence in activities of daily living, and positive user satisfaction \[[@CR3]\].

Limitations of the system were the requirement of external components, and being restricted to eight stimulations channels, which only enabled two grasp patterns, palmar and lateral. The control method for user operation required movement of the opposite shoulder to control grasp as well as lock and unlock grasp patterns. To address the described limitations, second \[[@CR4]\] and now third \[[@CR5]\] generation systems have been created. The second generation system, the Case Western Reserve University Implanted Stimulator-Telemeter (IST), increased the number of stimulation channels to 10 (IST-10) and later, 12 (IST-12), permitting additional functions such as forearm pronation and elbow extension, as well as customized grasps. It also internalized the control source, allowing the user to control operation based on myoelectric feedback in the same arm \[[@CR4]\]. The third generation system, the Case Western Reserve University Networked Neuroprosthesis (NNP) \[[@CR5]\], has no externally worn components and features a modular design, allowing the distribution of stimulators and electrodes throughout the body, enabling multiple functions to be restored.

Our interest is in exploring the willingness of people with SCI to accept the risks and benefits of this third-generation system when configured to provide upper extremity (UE) function (e.g., hand grasp). The goal of this survey was to query a large number of people living with tetraplegia to characterize the relative risk:benefit value and inform the design of a future pivotal trial for the UE configuration of the NNP.

Methods {#Sec2}
=======

Survey design {#Sec3}
-------------

A stated-preference study was performed utilizing direct-assessment questions. Stated-preference methodology refers to a family of techniques that use statements of individual respondents about their preferences to a set of hypothetical attributes \[[@CR6]--[@CR8]\]. The underlying theoretical framework of stated-preference methodology is ordinal-utility theory. Respondents are presented with a series of hypothetical choice problems and asked to state how they would behave in the situation. Ordinal-utility enables one to identify one preference over another, but cannot provide any information about the strength of preferences.

The survey questions were designed to explore perceptions of both risk and benefit of the NNP using estimates about its performance based on the earlier generation NeuroControl Freehand System, as reported in the product's approved labeling. Three categories of questions were included: (1) benefits of arm and hand function, (2) concern level of different adverse events that could potentially occur during the 30-day post-surgical period, and within the first 5 years after receiving the NNP implant, and (3) interest level in receiving a NNP given different threshold scenarios of benefit and risk. See [Supplementary Material](#MOESM1){ref-type="media"} for exact phrasing of questions.

To explore perceptions of benefit, participants were presented with a range of probabilities (90, 80, 65, 50, 10%) of achieving success and asked to rate their interest level in having the NNP implanted. The range of probabilities was chosen to span a realistic range of outcomes based on the Freehand study, plus lower probabilities in order to characterize worse case scenarios. Success was defined as achieving three specific outcomes with the neuroprosthetic: (1) an improvement in active movement of the arm, (2) an improvement in pinch or grasp strength in the hand, and (3) the ability to lift or move more everyday objects than before. This definition was selected because: (1) the NNP UE configuration has the potential to impact each function, (2) the clinical trial for the Freehand System used the same definition of success, and (3) this definition of success is being considered for a future pivotal clinical trial for the NNP UE configuration.

To explore perceptions of risk, we identified a low, medium, and high probability of experiencing types of risks associated with the acute (30 days) and long-term (5 years) use of the Freehand system. The medium point estimates were taken from the actual adverse event rate observed in the Freehand clinical trial. The low point estimate was then calculated by dividing the observed rate by two; and the high point estimate was established by doubling the observed rate. In two questions where the observed adverse event rate was already very low (1--2%), the observed rate was used as the low point estimate, with the medium and high estimates derived by multiplying this by two and four respectively. See the [Supplementary Material](#MOESM1){ref-type="media"} for details. Using a 1--7 Likert rating scale, participants were asked to identify the extent to which they agreed with or were concerned about the types and rates of adverse events. There were also seven basic demographic questions.

The questionnaire was administered online using the software program SurveyMonkey™ (San Mateo, CA, USA). A detailed description of SurveyMonkey™ security features is available at [www.surveymonkey.com/mp/policy/security/](http://www.surveymonkey.com/mp/policy/security/). All responses were immediately stored in a secured, computerized database. In an effort to not exclude individuals who did not have access to the Internet, the option of completing the survey via the postal mail or by telephone was provided; answers were immediately entered into the online survey upon receipt.

All survey questions and answer choices are available in the [Supplementary Material](#MOESM1){ref-type="media"}. The study was reviewed and approved by the University of Miami Institutional Review Board, where the corresponding author was located at the time the survey was conducted. We certify that all applicable institutional and governmental regulations concerning the ethical use of human volunteers were followed during the course of this research.

Participant recruitment {#Sec4}
-----------------------

To qualify for the study, individuals had to have a SCI, be 18 years of age or older, and have tetraplegia (via self-report). A waiver of signed consent was granted by the institution. All of the elements of informed consent were described on the study information page, which was displayed on the first page of the survey. Consent and qualification were inferred by agreement and further participation in the survey. Those individuals who did not agree to the information provided on the study information page elected to not complete the survey. Participants were recruited by word of mouth through people living with SCI, postings on the internet, and individuals in the Miami Project volunteer registry. Enrollment occurred between August and November 2017.

Data reporting and analyses {#Sec5}
---------------------------

All descriptive sample demographics were reported following the international SCI basic and core data set recommendations \[[@CR9], [@CR10]\]. For analytic purposes, all question responses were collapsed into three categories (positive, neutral, negative). Pearson and Likelihood Chi-square tests \[[@CR11]\] were used to identify associations between question responses and sex, injury level (C1-4 vs C5-8), or injury duration group (0--5 YPI vs 6--15 YPI vs 16 + YPI) (α = 0.05). For each significant association, the chi-square statistic of each cell was evaluated against a chi-square critical value corresponding to a Bonferonii corrected p value, which adjusted for the number of cells in the table (i.e., number of evaluations performed). The chi-square critical values for post-hoc evaluation were 7.037 for 2 × 3 tables (gender and injury level; *p* = 0.008 (α = 0.05/6 cells)) and 7.879 for 3 × 3 tables (injury duration, *p* = 0.005(α = 0.05/9 cells)). Cell chi-square values greater than or equal to these values were accepted as statistically significant. Data used to compute all contingency tables are presented in the [Supplementary Material](#MOESM1){ref-type="media"}.

Results {#Sec6}
=======

Demographics {#Sec7}
------------

The survey was emailed to 1424 individuals living with tetraplegia due to traumatic or non-traumatic cause and age ≥ 18 years; 3% of those emails bounced back, 4% opted out, and 32% responded (*N* = 457). Of the responders, 49 did not provide answers to all of the questions so the analyses presented here are for the 408 participants who completed the entire survey. The population was 78% male with 67% reporting cervical 5--8 lesion level. The mean age and standard deviation of the population was 43 ± 14 years (43, 18--83 \[median, range\]) and the mean post-injury duration was 13 ± 12 years (9, \<1--82 \[median, range\]). The primary cause of injury, distribution of post-injury duration, primary mode of mobility, and secondary mode of mobility are provided in Table [1](#Tab1){ref-type="table"}.Table 1DemographicsSexMale78% (*N* = 317)Female22% (*N* = 91)Age43 ± 14 yearsCause of SCITransport45% (*N* = 185)Sports30% (*N* = 121)Fall12% (*N* = 50)Other traumatic6% (*N* = 23)Assault3% (*N* = 13)Non-traumatic3% (*N* = 11)Unknown1% (*N* = 5)Location of SCICervical 1--433% (*N* = 135)Cervical 5--867% (*N* = 273)Years post-Injury (YPI)13 ± 12 years0--5 yrs32% (*N* = 129)6--15 yrs37% (*N* = 151)16 + yrs31% (*N* = 128)Primary mode of mobilityPower wheelchair56% (*N* = 230)Scooter1% (*N* = 5)Manual w/c25% (*N* = 104)Power-assist w/c6% (*N* = 23)Walk w/ devices6% (*N* = 24)Walk independent5% (*N* = 22)Secondary mode of mobilityNo51% (*N* = 210)Power wheelchair11% (*N* = 44)Scooter1% (*N* = 5)Manual w/c22% (*N* = 89)Power-assist w/c6% (*N* = 24)Walk w/ devices7% (*N* = 29)Walk independent2% (*N* = 7)

Functional improvement {#Sec8}
----------------------

There were 8 statements about improved UE function; for all statements, more than 70% of participants rated the functions as "1-very important" to regain (Fig. [1](#Fig1){ref-type="fig"}). There was no statistical difference in association between sex and question responses (Table [2](#Tab2){ref-type="table"}). There were limited associations between injury level or injury duration and responses (Table [2](#Tab2){ref-type="table"}), but post-hoc analyses did not reveal where those differences were located. Visual inspection of the data did not reveal any trends between groups (see [Supplementary Material](#MOESM1){ref-type="media"}).Fig. 1Importance of upper extremity functions. (*ADLs* activities of daily living, *w/o* without)Table 2Chi-squared analyses of associations between question responses and sex, injury level, and injury durationCategoryDescriptionSex^a^Injury level^a^Injury duration^b^BenefitsImproved active movement of armNSNSNSOpen your handNSL*χ*^2^ 10.49, *p* = 0.005NSClose your handNSL*χ*^2^ 9.04, *p* = 0.011L*χ*^2^ 12.64, *p* = 0.013Pinch or grasp strength in your handNSNSNSPick up everyday objectsNSNSNSADLs w/o help from personNSNSNSHand activities w/o adaptive equipmentNSNSNSHand activities w/o person or equipmentNSNSNSRisksPost-surgical infection that requires treatmentP*χ*^2^ 10.22, *p* = 0.006NSNSTemporary, post-surgical painNSNSNSTemporary reduction in arm or hand functionNSP*χ*^2^ 6.93, *p* = 0.031NSCorrected without surgeryNSNSNSOutpatient surgeryNSNSNSInpatient surgeryNSNSNSRemove 1 or more componentsNSNSNSRemove entire systemNSNSNSReplace battery every 5 yearNSNSNSThresholdsSuccessInterest in NNP if 90% chance of achieving successNSNSL*χ*^2^ 10.26, *p* = 0.036Interest in NNP if 80% chance of achieving successL*χ*^2^ 7.69, *p* = 0.021NSNSInterest in NNP if 65% chance of achieving successP*χ*^2^ 5.56, *p* = 0.062NSP*χ*^2^ 10.71, *p* = 0.030Interest in NNP if 50% chance of achieving successP*χ*^2^ 7.02, *p* = 0.029NSNSInterest in NNP if 10% chance of achieving successP*χ*^2^ 11.39, *p* = 0.003NSNSRiskInterest in NNP if 1% chance of infectionNSNSL*χ*^2^ 14.45, *p* = 0.006Interest in NNP if 2% chance of infectionP*χ*^2^ 7.51, *p* = 0.023NSP*χ*^2^ 12.07, *p* = 0.017Interest in NNP if 4% chance of infectionP*χ*^2^ 9.50, *p* = 0.083NSP*χ*^2^ 10.68, *p* = 0.030Interest in NNP if 10% chance of painNSNSL*χ*^2^ 12.97, *p* = 0.011Interest in NNP if 20% chance of painNSNSP*χ*^2^ 10.19, *p* = 0.037Interest in NNP if 40% chance of painNSNSP*χ*^2^ 16.63, *p* = 0.002Interest in NNP if temp reduction arm functionNSNSP*χ*^2^ 10.58, *p* = 0.032Interest in NNP if 25% chance fix w/o surgeryNSNSNSInterest in NNP if 50% chance fix w/o surgeryNSNSNSInterest in NNP if 100% chance fix w/o surgeryNSNSNSInterest in NNP if 5% chance fix w/ Outpt surgeryNSNSNSInterest in NNP if 10% chance fix w/ Outpt surgeryP*χ*^2^ 8.15, *p* = 0.017NSNSInterest in NNP if 20% chance fix w/ Outpt surgeryNSNSNSInterest in NNP if 10% chance fix w/ Inpt surgeryP*χ*^2^ 9.23, *p* = 0.009NSNSInterest in NNP if 20% chance fix w/ Inpt surgeryNSNSP*χ*^2^ 10.83, *p* = 0.029Interest in NNP if 40% chance fix w/ Inpt surgeryNSNSP*χ*^2^ 10.18, *p* = 0.038Interest in NNP if 5% chance remove 1 + partsP*χ*^2^ 6.89, *p* = 0.032NSNSInterest in NNP if 10% chance remove 1 + partsNSNSP*χ*^2^ 13.64, *p* = 0.009Interest in NNP if 20% chance remove 1 + partsNSNSP*χ*^2^ 11.56, *p* = 0.021Interest in NNP if 2% chance remove All partsP*χ*^2^ 7.52, *p* = 0.023NSP*χ*^2^ 10.64, *p* = 0.031Interest in NNP if 4% chance remove All partsNSNSNSInterest in NNP if 8% chance remove All partsP*χ*^2^ 12.30, *p* = 0.002NSNSInterest in NNP if replace battery 3 yr w/ Outpt surgeryP*χ*^2^ 7.19, *p* = 0.027NSP*χ*^2^ 12.16, *p* = 0.016Interest in NNP if replace battery 5 yr w/ Outpt surgeryNSNSP*χ*^2^ 11.41, *p* = 0.022Interest in NNP if replace battery 7 yr w/ Outpt surgeryP*χ*^2^ 6.69, *p* = 0.035P*χ*^2^ 9.98, *p* = 0.007NS^a^degrees of freedom = 2^b^degrees of freedom = 4*χ* and *p* values are not corrected for multiple comparisons*NS* not significant, *Pχ*^2^ Pearson's chi-square, *Lχ*^*2*^ Likelihood ratio chi-square, *Outpt* outpatient, *Inpt* inpatient, *NNP* networked Neuroprosthesis

Potential risks {#Sec9}
---------------

The next topic of inquiry was about possible risks that could be associated with implanted devices such as the NNP. There were variable degrees of concern related to risks that could occur during the 30-day post-surgical period (Fig. [2a](#Fig2){ref-type="fig"}). There was no difference in association between injury duration and question responses (Table [2](#Tab2){ref-type="table"}). There were limited associations between sex or injury level and responses (Table [2](#Tab2){ref-type="table"}), but post-hoc analyses did not reveal where those differences were located. Visual inspection of the data suggested a trend for females and people with C5--8 injury levels to be more conservative about risk than men or people with C1--4 injury levels (see [Supplementary Material](#MOESM1){ref-type="media"}). The second category of risks included those that could occur during the first 5 years and potentially be related to the implant. There were increasing degrees of concern related to these risks based on the increasing degree of invasiveness of the intervention required to address the event (Fig. [2b](#Fig2){ref-type="fig"}). There was no difference in association between sex, injury level, or injury duration and question responses (Table [2](#Tab2){ref-type="table"}).Fig. 2Concern about risks potentially associated with implanted devices like the Networked Neuroprosthesis (NNP). **a** Degree of concern about risks that could occur within the 30-day post-surgical period and be associated with the surgical procedure or location of implant. **b** Degree of concern about risks that could occur during the first 5 years and potentially be related to the implant. (*w/o* without, *w/* with, *surg* surgery, *outpt* outpatient, *inpt* inpatient, 1+= 1 or more)

Threshold scenarios {#Sec10}
-------------------

The first threshold scenario was designed to investigate the tolerability of different thresholds of success. Figure [3](#Fig3){ref-type="fig"} shows the results for all respondents. There was no difference in association between injury level and question responses (Table [2](#Tab2){ref-type="table"}). There were multiple associations between sex and responses and two associations between injury duration and responses (Table [2](#Tab2){ref-type="table"}), but post-hoc analyses did not reveal where those differences were located. Visual inspection of the data suggested a trend for females and people who were 16 or more years' post-injury to be more conservative about risk than men or people with shorter injury durations (see [Supplementary Material](#MOESM1){ref-type="media"}).Fig. 3Participant interest in the Networked Neuroprosthesis (NNP) in different scenarios of success

The second threshold scenario was designed to investigate the tolerability of different thresholds of risk. For all respondents, Fig. [4](#Fig4){ref-type="fig"} shows the threshold variance related to the short-term post-surgical risks and Fig. [5](#Fig5){ref-type="fig"} shows the threshold variance for the later device-related risks. Interest levels increased or decreased as risk probabilities decreased or increased. There was only 1 difference in association between injury level and question responses (Table [2](#Tab2){ref-type="table"}). There were multiple associations between sex and responses and several associations between injury duration and responses (Table [2](#Tab2){ref-type="table"}), but post-hoc analyses did not reveal where those differences were located. Visual inspection of the data suggested a consistent trend for females and people who were 16 or more years' post-injury to be more conservative about risk than men or people with shorter injury durations (see [Supplementary Material](#MOESM1){ref-type="media"}).Fig. 4Tolerability of risk thresholds during the first 30 days. **a** Interest in the Networked Neuroprosthesis (NNP) under low, medium, and high probability of experiencing a post-surgical infection requiring treatment. **b** Interest in the NNP under low, medium, and high probability of experiencing post-surgical pain. **c** Interest in the NNP if there were a temporary reduction in upper extremity function due to immobilizationFig. 5Tolerability of risk thresholds during the first 5 years. Interest in the Networked Neuroprosthesis (NNP) under low, medium, and high probability of experiencing a problem **a** that could be corrected without surgery, **b** that could be corrected with outpatient surgery, **c** that could be corrected with inpatient surgery, **d** requiring removal of one or more components of the device, **e** requiring the removal of the whole system. **f** Interest in the NNP if the need to undergo outpatient surgery to replace the battery were every 3, 5, or 7 years

Discussion {#Sec11}
==========

These results indicate that individuals living with tetraplegia are very interested in interventions that target UE function. Further, they are tolerant to varying degrees of potential risks associated with implanted neuroprosthetic devices. There were trends for differences in risk tolerance based on sex and time post-injury, but when put in the context of the estimated probability of experiencing a particular risk, there was overall interest in receiving an implanted neuroprosthetic device that can provide similar outcomes as the Freehand system, for both benefits and risks.

Functional improvement {#Sec12}
----------------------

We asked participants about eight improvements in the UE that the NNP could potentially provide. All functions were rated overwhelmingly as very important, almost to the point of appearing as a ceiling effect. It is unlikely that these responses are strictly related to the NNP device. We postulate that any intervention that could impact those functions would likely also be rated as highly important by people with tetraplegia. Examples of such interventions could include nerve transfers, tendon transfers, surface FES, implanted neuroprosthetics, potential drugs, and biologics targeting UE function.

Regaining UE function has been documented as a high priority for people with tetraplegia for many years. Anderson \[[@CR12]\] prospectively queried 681 people living with chronic SCI to identify functional return that would most improve quality of life. Fifty-one percent of respondents had tetraplegia and regaining arm/hand function was the highest ranked desired return (48.7%). Donnelly \[[@CR13]\] demonstrated retrospectively that in the early rehabilitation period self-care goals were most frequently cited as important by people with SCI. Snoek \[[@CR14]\] performed a prospective survey in the Dutch and United Kingdom tetraplegic communities and determined that regaining hand function was very important to improving quality of life. A systematic review of perceived importance of life domains and priorities of people with SCI reinforced the finding that regaining arm and hand function was consistently a high priority for people living with tetraplegia \[[@CR15]\]. This reinforces how important these functions are for people living with tetraplegia.

For each of the eight functions queried, there was also a small portion of responders that rated them as "somewhat unimportant", "unimportant", or "very unimportant". It is possible that those individuals already had adequate function in those activities and therefore rated them as unimportant to restore. This could be a reflection of the heterogeneity of cervical injuries, however the overall number of responders stating the UE functions were unimportant was small. These responses may also reflect a small proportion of responders not interested in any neurotechnology.

Risks and benefits {#Sec13}
------------------

When trading off the potential risks and benefits of the NNP, respondents were interested in receiving the system when the hypothetical outcomes matched the observed outcomes for the previously-FDA-approved NeuroControl Freehand system. However, even when the hypothetical outcome posed substantially more risk (e.g. doubling the adverse event rate over what was observed with Freehand), respondents still remained highly interested in receiving the system. This suggests that there is a high degree of risk tolerance for implantable neuroprosthetics that provide meaningful functional UE outcomes. It also suggests that an UE neuroprosthesis could enjoy widespread acceptance by the user community, within a fairly wide range of outcomes for a clinical trial.

Across several threshold scenarios, females and people injured 16 or more years were more conservative in their definition of success and risk tolerance. We postulate that this could be related to many complex factors worthy of further investigation. With increasing time post-injury, people develop a longer health experience related to their SCI. It is possible that they may be warier of interventions that could have a potential negative impact on their health. Similarly, they may be more likely to have an established routine that provides stability for them and may be hesitant to introduce change to that routine. It is also possible that they may have been compensating for many years to achieve degrees of function by whatever means possible and they may be fearful of losing those gains. These concepts were identified in a qualitative study evaluating readiness for stem cell clinical trials, and people with chronic SCI were less receptive to participating in such trials than people with subacute injuries for similar reasons as postulated above \[[@CR16]\].

Further, people who have lived with their SCI for shorter durations may still be seeking improvements or interventions on a more active level and, therefore, may be more risk tolerant. Disease duration has been shown to impact risk tolerance in multiple sclerosis. Individuals with a longer disease duration demonstrate a greater tolerance of risk, presumably related to the progressive nature of multiple sclerosis \[[@CR17], [@CR18]\]. SCI is not progressive, but just the opposite. Initially, this catastrophic event impacts every aspect of life and it is only with increasing time post-injury that people cope, adapt, and develop stability \[[@CR19], [@CR20]\]. Hence, their risk tolerance may mirror that process. Similarly, females living with multiple sclerosis have lower risk tolerance to therapies than males \[[@CR18]\]. Further investigation related to reasons why females with SCI may have lower risk tolerance to therapies is required.

Study limitations {#Sec14}
-----------------

We acknowledge the limitations of this survey; it was administered primarily on-line. Our sample could therefore be biased towards persons who frequent the Internet. The Internet has become a prominent means of gathering resource information and has removed multiple barriers for many people living with disabilities worldwide \[[@CR21], [@CR22]\]. Previous studies show that people living with SCI prefer to receive research information from the Internet \[[@CR23]\].

We did purposefully keep the survey short in an effort to make it less cumbersome and burdensome to participants. The primary limitation of stated-preference data is that the choices are hypothetical. Respondents may not know how they would actually respond when faced with the real situation of deciding to undergo implantation of the NNP, or any invasive procedure for that matter. Additionally, people responded to each attribute individually, not to a profile of attributes. Future studies will involve methodology to gain information about tradeoffs people are willing to take related to various risk:benefit combinations.

Conclusion {#Sec15}
==========

Potential end users of investigational interventions not only will gain the benefits of such therapeutics, but also will bear any potential harms. Understanding how they weigh benefits and risks can help prioritize engineering decisions on design, device improvements, troubleshooting, clinical trial design, and functional targets. Therefore, it is critical to engage end users early and often in research and development of therapeutic interventions. Data here indicate that people with tetraplegia are highly interested in a range of UE benefits and are appropriately tolerant of expected risks associated with neuroprosthetics, but sex and injury duration may influence risk:benefit preferences.
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